Nalaganje...
Targeting DNA damage repair in small cell lung cancer and the biomarker landscape
Small cell lung cancer (SCLC) is an aggressive malignancy that accounts for 14% of all lung cancer diagnoses. Despite decades of active research, treatment options for SCLC are limited and resistance to the few Food and Drug Administration (FDA) approved therapies develops rapidly. With no approved...
Shranjeno v:
| izdano v: | Transl Lung Cancer Res |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
AME Publishing Company
2018
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5835589/ https://ncbi.nlm.nih.gov/pubmed/29535912 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr.2018.02.03 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|